Beth DelGiacco
VP and Global Head of Corporate Communications & Investor Relations
Good afternoon. Welcome. My name is Beth DelGiacco, I’m the Head of Communications and Investor Relations at argenx. I want to first give a warm welcome to everybody in the room. We have some of our analysts and investors. Many of our colleagues here today, our Board members. So yes, a big welcome. This is our first of what we’re calling an R&D Spotlight, and we’re spotlighting today ARGX-119. This is our MuSK agonist. And I want to spend a little time quickly on why we’ve decided to host these series of events.
For those who have a bit of a longer memory, early in the days of efgartigimod development, we would host these pretty often. And it was usually around rolling out a new indication or ahead of data, and we actually had the request to bring this concept back. And we’re happy to do it. I think it’s very much core to who we are. We’re very science-based. We’re data-driven. So you’re going to see more of these next week.
It’s also the right time to really be spotlighting ARGX-119. We had a go decision in this molecule into CMS in
Read the full article here
